NIH PAR · NHLBI · R61, R33
PAR-25-026: NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award where the…
- NOFO number
- PAR-25-026
- Type
- PAR
- Activity code
- R61R33
- Primary institute
- NHLBI · National Heart, Lung, and Blood Institute
- Clinical trials
- Required
- Posted
- Dec 5, 2024
- Opens
- Jan 3, 2025
- Expires
- Jan 8, 2027
PAR-25-026 due dates
No application due dates remain in the listed cycles. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 03, 2025 | February 03, 2025 | May 07, 2025 * | July 2025 | October 2025 | December 2025 |
| June 04, 2025 | June 04, 2025 | September 07, 2025 * | November 2025 | January 2026 | April 2026 |
| October 02, 2025 | October 02, 2025 | January 07, 2026 * | March 2026 | May 2026 | July 2026 |
| February 03, 2026 | February 03, 2026 | May 07, 2026 * | July 2026 | October 2026 | December 2026 |
| June 04, 2026 | June 04, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 02, 2026 | October 02, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
Projects funded under PAR-25-026
NIH RePORTER lists 2 projects funded under PAR-25-026 in FY2022–FY2026, with $868K in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
2
Distinct projects, FY2022–FY2026
New awards
2
Type 1 (new project) award records
NIH funding
$868K
Award dollars under PAR-25-026, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 2 | 2 | $868K |
Institutions with the most funding
- Hackensack University Medical Center$471K · 1 project
- Utah State Higher Education System--University of Utah$398K · 1 project
Funding institutes
- NHLBI$868K · 2
Activity codes funded
- R612 records
Most recent new awards
- Safety and Pharmacodynamics of L-Citrulline for the Treatment of Pulmonary Hypertension (PH) in Preterm Neonates with Severe Bronchopulmonary Dysplasia (BPD-PH) [CToP BPD-PH] (opens NIH RePORTER)
Hackensack University Medical Center · 1R61HL185680-01 · NHLBI · Notice Sep 4, 2026
$471KR61
- Phase 1 clinical trial of complement inhibition in primary graft dysfunction after lung transplantation (opens NIH RePORTER)
Utah State Higher Education System--University of Utah · 1R61HL187358-01 · NHLBI · Notice Aug 27, 2026
$398KR61
What its predecessor PAR-24-173 funded
PAR-25-026 reissues PAR-24-173. Its funding history is the best guide to who wins under this program: 1 project and $445K in FY2022–FY2026.
Projects funded
1
Distinct projects, FY2022–FY2026
New awards
1
Type 1 (new project) award records
NIH funding
$445K
Award dollars under PAR-24-173, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 1 | 1 | $445K |
| FY2026 | 0 | 0 | $0 |
Institutions with the most funding
- Indiana University Indianapolis$445K · 1 project
Funding institutes
- NHLBI$445K · 1
Activity codes funded
- R611 record
Most recent new awards
- CHERISH (duCHennE caRdiomyopathy mItigation Sglt2 inHibitor) (opens NIH RePORTER)
Indiana University Indianapolis · 1R61HL180327-01 · NHLBI · Notice Sep 3, 2025
$445KR61
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-026. Contact the program officer at the institute that fits your research before applying.
- NHLBI · National Heart, Lung, and Blood Institute
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Award terms
- Application types allowed
- NewResubmissionRevision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets in the R61 phase are limited to 250,000 in direct costs per year. Application budgets in the R33 phase should not exceed 1,515,000 in direct costs per year.
- Project period
- The maximum period of the combined R61 and R33 phases is 5 years, with up to 2 years for the R61 phase and up to 3 years for the R33 phase. The scope of the proposed project should determine the requested project period.      NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-24-173.
- Companion NOFOs: PAR-25-025.
Other open NOFOs for R61, R33
- RFA-HL-26-016Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)NHLBI · next due Oct 21, 2026
- RFA-HL-26-017Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)NHLBI · next due Oct 21, 2026
- RFA-HL-26-018Catalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)NHLBI · next due Oct 21, 2026
- RFA-HL-26-019Catalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)NHLBI · next due Oct 21, 2026
- RFA-HL-26-020Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)NHLBI · next due Oct 21, 2026
- PAR-27-011Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)NHLBI · next due Feb 1, 2027
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.